| Author | Ranzani, Otavio T. | |
| Author | Silva, Amanda A. B. | |
| Author | Peres, Igor T. | |
| Author | Antunes, Bianca B. P. | |
| Author | Gonzaga-da-Silva, Thiago W. | |
| Author | Soranz, Daniel R. | |
| Author | Cerbino-Neto, José | |
| Author | Hamacher, Silvio | |
| Author | Bozza, Fernando A. | |
| Access date | 2022-05-25T19:58:54Z | |
| Available date | 2022-05-25T19:58:54Z | |
| Document date | 2022 | |
| Citation | RANZANI, Otavio T. et al. Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study. Clinical Microbiology and Infection, v. 28, n. 5, p. 1-5, 2022. | pt_BR |
| ISSN | 1198-743X | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/52888 | |
| Language | eng | pt_BR |
| Publisher | Elsevier | pt_BR |
| Rights | open access | |
| Title | Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study | pt_BR |
| Type | Article | |
| DOI | 10.1016/j.cmi.2022.01.032 | |
| Abstract | Objectives: To estimate vaccine effectiveness after the first and second dose of ChAdOx1 nCoV-19 against symptomatic COVID-19 and infection in a socially vulnerable community in Brazil when Gamma and Delta were the predominant variants circulating.
Methods: We conducted a test-negative study in the community Complexo da Maré, the largest group of slums (n = 16) in Rio de Janeiro, Brazil, from January 17, 2021 to November 27, 2021. We selected RT-qPCR positive and negative tests from a broad community testing program. The primary outcome was symptomatic COVID-19 (positive RT-qPCR test with at least one symptom) and the secondary outcome was infection (any positive RT-qPCR test). Vaccine effectiveness was estimated as 1 - OR, which was obtained from adjusted logistic regression models.
Results: We included 10 077 RT-qPCR tests (6,394, 64% from symptomatic and 3,683, 36% from asymptomatic individuals). The mean age was 40 (SD: 14) years, and the median time between vaccination and RT-qPCR testing among vaccinated was 41 (25-75 percentile: 21-62) days for the first dose and 36 (25-75 percentile: 17-59) days for the second dose. Adjusted vaccine effectiveness against symptomatic COVID-19 was 31.6% (95% CI, 12.0-46.8) 21 days after the first dose and 65.1% (95% CI, 40.9-79.4) 14 days after the second dose. Adjusted vaccine effectiveness against COVID-19 infection was 31.0% (95% CI, 12.7-45.5) 21 days after the first dose and 59.0% (95% CI, 33.1-74.8) 14 days after the second dose.
Discussion: ChAdOx1 nCoV-19 was effective in reducing symptomatic COVID-19 in a socially vulnerable community in Brazil when Gamma and Delta were the predominant variants circulating. | pt_BR |
| Affilliation | Barcelona Institute for Global Health. ISGlobal. Universitat Pompeu Fabra. CIBER Epidemiología y Salud Pública. Barcelona, Spain / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clinicas HCFMUSP. Instituto do Coração. Divisão Pulmonar.São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Pontifícia Universidade Católica do Rio de Janeiro. Departamento de Engenharia Industrial e Instituto Tecgraf. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Pontifícia Universidade Católica do Rio de Janeiro. Departamento de Engenharia Industrial e Instituto Tecgraf. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Pontifícia Universidade Católica do Rio de Janeiro. Departamento de Engenharia Industrial e Instituto Tecgraf. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Secretaria Municipal de Saúde do Rio de Janeiro. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil / Secretaria Municipal de Saúde do Rio de Janeiro. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Secretaria Municipal de Saúde do Rio de Janeiro. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Pontifícia Universidade Católica do Rio de Janeiro. Departamento de Engenharia Industrial e Instituto Tecgraf. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Instituto D'Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Subject | Brazil | pt_BR |
| Subject | COVID-19 | pt_BR |
| Subject | Test-negative | pt_BR |
| Subject | Vaccine | pt_BR |
| Subject | Vulnerable community | pt_BR |
| xmlui.metadata.dc.subject.ods | 01 Erradicação da pobreza | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
